Log in

Relevant bibliographies by topics / Molecular radiotherapy / Journal articles

To see the other types of publications on this topic, follow the link: Molecular radiotherapy.

Journal articles on the topic 'Molecular radiotherapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 7 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Molecular radiotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Buscombe, John, and Shaunak Navalkissoor. "Molecular radiotherapy." Clinical Medicine 12, no. 4 (2012): 381–86. http://dx.doi.org/10.7861/clinmedicine.12-4-381.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Buscombe, JohnR. "Clinical Trials and Molecular Radiotherapy." World Journal of Nuclear Medicine 14, no. 2 (2015): 73. http://dx.doi.org/10.4103/1450-1147.154227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

D’Arienzo, Marco, Marco Capogni, Vere Smyth, et al. "Metrological Issues in Molecular Radiotherapy." EPJ Web of Conferences 77 (2014): 00022. http://dx.doi.org/10.1051/epjconf/20147700022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gaze, M. N., and G. D. Flux. "Molecular radiotherapy — the radionuclide raffle?" British Journal of Radiology 83, no. 996 (2010): 995–97. http://dx.doi.org/10.1259/bjr/32706189.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Glatting, Gerhard, Manuel Bardiès, and Michael Lassmann. "Treatment planning in molecular radiotherapy." Zeitschrift für Medizinische Physik 23, no. 4 (2013): 262–69. http://dx.doi.org/10.1016/j.zemedi.2013.03.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Price, Pat. "Molecular imaging to improve radiotherapy." Radiotherapy and Oncology 78, no. 3 (2006): 233–35. http://dx.doi.org/10.1016/j.radonc.2006.01.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Marples, B., O. Greco, M. C. Joiner, and S. D. Scott. "Molecular approaches to chemo-radiotherapy." European Journal of Cancer 38, no. 2 (2002): 231–39. http://dx.doi.org/10.1016/s0959-8049(01)00367-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wadsley, J., and G. Flux. "Molecular Radiotherapy Comes of Age." Clinical Oncology 33, no. 2 (2021): 65–67. http://dx.doi.org/10.1016/j.clon.2020.12.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Chorna, Inna. "MOLECULAR MECHANISMS UNDERLYING CANCER CELL RADIORESISTANCE." Scientific Journal of Polonia University 48, no. 5 (2022): 142–51. http://dx.doi.org/10.23856/4818.

Full text

Abstract:

Radioresistance of the tumor cells remains a significant obstacle for the radiotherapy treatment of cancer. Radioresistance involves multiple genes, factors, and mechanisms that adapt cancer cells or tissues to radiotherapy-induced changes and develop resistance to ionizing radiation. The major studies of the effect of radiation on cells reported include the following areas: 1) the study of DNA damages and their repair; 2) mutations in tumor suppressor genes and radiation-induced oncogene expression; 3) the role of growth factors and cytokines; 4) violation of the cell cycle; 5) elucidation of

APA, Harvard, Vancouver, ISO, and other styles

10

Murray, Iain, and Glenn Flux. "Applying radiobiology to clinical molecular radiotherapy." Nuclear Medicine and Biology 100-101 (September 2021): 1–3. http://dx.doi.org/10.1016/j.nucmedbio.2021.05.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

CHEN, YUE, ZHITING TANG, MIAO YU, RUI ZHANG, XINXIN DONG, and LIANQUN CAO. "Molecular biomarkers: multiple roles in radiotherapy." BIOCELL 44, no. 4 (2020): 513–24. http://dx.doi.org/10.32604/biocell.2020.09422.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Flux, Glenn, and John Buscombe. "BNMS position statement on molecular radiotherapy." Nuclear Medicine Communications 42, no. 10 (2021): 1061–63. http://dx.doi.org/10.1097/mnm.0000000000001458.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Flux, Glenn D., Joe O'Sullivan, Mark N. Gaze, and Kevin M. Prise. "Opportunities for research in molecular radiotherapy." British Journal of Radiology 90, no. 1071 (2017): 20160921. http://dx.doi.org/10.1259/bjr.20160921.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Harrington, K. "SP-0408: Molecular targeting with radiotherapy." Radiotherapy and Oncology 119 (April 2016): S190. http://dx.doi.org/10.1016/s0167-8140(16)31657-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Flux, G. "SP-0558: Update on molecular radiotherapy." Radiotherapy and Oncology 123 (May 2017): S299. http://dx.doi.org/10.1016/s0167-8140(17)30998-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Dutreix, M., J. M. Cosset, and J. S. Sun. "Molecular therapy in support to radiotherapy." Mutation Research/Reviews in Mutation Research 704, no. 1-3 (2010): 182–89. http://dx.doi.org/10.1016/j.mrrev.2010.01.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Konijnenberg, Mark. "Dosimetry based optimisation in molecular radiotherapy." Physica Medica 32 (September 2016): 189. http://dx.doi.org/10.1016/j.ejmp.2016.07.329.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Bailey, Dale L., Wendy Philips, and Clive Baldock. "The future of radiotherapy is molecular." Physical and Engineering Sciences in Medicine 43, no. 3 (2020): 755–59. http://dx.doi.org/10.1007/s13246-020-00917-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Rey, Sergio, Luana Schito, Marianne Koritzinsky, and Bradly G. Wouters. "Molecular targeting of hypoxia in radiotherapy." Advanced Drug Delivery Reviews 109 (January 2017): 45–62. http://dx.doi.org/10.1016/j.addr.2016.10.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Aldridge, M. D., C. Peet, S. Wan, et al. "Paediatric Molecular Radiotherapy: Challenges and Opportunities." Clinical Oncology 33, no. 2 (2021): 80–91. http://dx.doi.org/10.1016/j.clon.2020.11.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Cansu Şahin, Meryem, Fatih Kar, and Meliha Koldemir Gündüz. "Brain metastases: Radiobiological, molecular and biochemical approach." Demiroglu Science University Florence Nightingale Journal of Medicine 7, no. 2 (2021): 179–89. http://dx.doi.org/10.5606/fng.btd.2021.25065.

Full text

Abstract:

Radiotherapy has made remarkable technological progress in recent years. The accuracy of radiotherapy has improved significantly, and accordingly, the treatment of tumors with high-dose radiation has become possible. Stereotactic radiosurgery has become a rapidly accepted method for the treatment of solid small-sized tumors. Compared to conventional fractionation radiotherapy, stereotactic radiosurgery with a very high dose per fraction and hypofractionated radiotherapy provides satisfactory therapeutic efficiency with low toxicity as tumor cells can be ablated directly with this method. Stere

APA, Harvard, Vancouver, ISO, and other styles

22

Giaccia, Amato J. "Molecular Radiobiology: The State of the Art." Journal of Clinical Oncology 32, no. 26 (2014): 2871–78. http://dx.doi.org/10.1200/jco.2014.57.2776.

Full text

Abstract:

Traditional cytotoxic agents used in cancer therapy were initially discovered based on their ability to kill rapidly dividing cells. The targets of these early-generation agents were typically one or more aspects of DNA synthesis or mitosis. Thus, dose-limiting toxicities commonly associated with these agents include GI dysfunction, immunosuppression, and other consequences of injury to normal tissues in which cells are replicating under normal physiologic conditions. Although many of these agents still play an important role in cancer therapy when given concurrently with radiation therapy, th

APA, Harvard, Vancouver, ISO, and other styles

23

Matschke, Johann, Safa Larafa, and Verena Jendrossek. "Metabolic reprograming of antioxidant defense: a precision medicine perspective for radiotherapy of lung cancer?" Biochemical Society Transactions 49, no. 3 (2021): 1265–77. http://dx.doi.org/10.1042/bst20200866.

Full text

Abstract:

Radiotherapy plays a key role in the management of lung cancer patients in curative and palliative settings. Traditionally, radiotherapy was either given alone or in combination with surgery, classical cytotoxic chemotherapy, or both. Technical and physical innovations achieved during the last two decades have helped to enhance the accuracy of radiotherapy dose delivery and have facilitated geometric radiotherapy individualization. Furthermore, multimodal combinations with molecularly tailored drugs or immunotherapy yielded promising survival benefits in selected patients. Yet high locoregiona

APA, Harvard, Vancouver, ISO, and other styles

24

Blomain, Erik S., and Everett J. Moding. "Liquid Biopsies for Molecular Biology-Based Radiotherapy." International Journal of Molecular Sciences 22, no. 20 (2021): 11267. http://dx.doi.org/10.3390/ijms222011267.

Full text

Abstract:

Molecular alterations drive cancer initiation and evolution during development and in response to therapy. Radiotherapy is one of the most commonly employed cancer treatment modalities, but radiobiologic approaches for personalizing therapy based on tumor biology and individual risks remain to be defined. In recent years, analysis of circulating nucleic acids has emerged as a non-invasive approach to leverage tumor molecular abnormalities as biomarkers of prognosis and treatment response. Here, we evaluate the roles of circulating tumor DNA and related analyses as powerful tools for precision

APA, Harvard, Vancouver, ISO, and other styles

25

Gains, J. E., J. B. Bomanji, N. L. Fersht, et al. "177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma." Journal of Nuclear Medicine 52, no. 7 (2011): 1041–47. http://dx.doi.org/10.2967/jnumed.110.085100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

McGowan, D. R., and M. J. Guy. "Time to demand dosimetry for molecular radiotherapy?" British Journal of Radiology 88, no. 1047 (2015): 20140720. http://dx.doi.org/10.1259/bjr.20140720.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

R. Weichselbaum, Donald W. Kufe, Su, Ralph. "Molecular Targeting of Gene Therapy and Radiotherapy." Acta Oncologica 40, no. 6 (2001): 735–38. http://dx.doi.org/10.1080/02841860152619151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Izard, M. A. "A role for molecular radiobiology in radiotherapy?" Clinical Oncology 9, no. 5 (1997): 349. http://dx.doi.org/10.1016/s0936-6555(05)80072-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Gordon, A. T., and T. J. McMillan. "A role for molecular radiobiology in radiotherapy?" Clinical Oncology 9, no. 2 (1997): 70–78. http://dx.doi.org/10.1016/s0936-6555(05)80443-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Baumann, Michael, Mechthild Krause, Daniel Zips, et al. "Molecular targeting in radiotherapy of lung cancer." Lung Cancer 45 (August 2004): S187—S197. http://dx.doi.org/10.1016/j.lungcan.2004.07.975.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Jeraj, R. "SP-0493: Molecular imaging for radiotherapy optimisation." Radiotherapy and Oncology 119 (April 2016): S234. http://dx.doi.org/10.1016/s0167-8140(16)31743-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Yarnold, John. "Molecular aspects of cellular responses to radiotherapy." Radiotherapy and Oncology 44, no. 1 (1997): 1–7. http://dx.doi.org/10.1016/s0167-8140(97)00049-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Ashrafizadeh, Milad, Bagher Farhood, Ahmed Eleojo Musa, Shahram Taeb, and Masoud Najafi. "Damage-associated molecular patterns in tumor radiotherapy." International Immunopharmacology 86 (September 2020): 106761. http://dx.doi.org/10.1016/j.intimp.2020.106761.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Price, Emlyn, Andrew P. Robinson, David M. Cullen, et al. "Improving molecular radiotherapy dosimetry using anthropomorphic calibration." Physica Medica 58 (February 2019): 40–46. http://dx.doi.org/10.1016/j.ejmp.2019.01.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Li, Haonan, Qiyong Gong, and Kui Luo. "Biomarker-driven molecular imaging probes in radiotherapy." Theranostics 14, no. 10 (2024): 4127–46. http://dx.doi.org/10.7150/thno.97768.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Filice, Angelina, Massimiliano Casali, Patrizia Ciammella, et al. "Radiotherapy Planning and Molecular Imaging in Lung Cancer." Current Radiopharmaceuticals 13, no. 3 (2020): 204–17. http://dx.doi.org/10.2174/1874471013666200318144154.

Full text

Abstract:

Introduction: In patients suitable for radical chemoradiotherapy for lung cancer, 18F-FDGPET/ CT is a proposed management to improve the accuracy of high dose radiotherapy. However, there is a high rate of locoregional failure in patients with locally advanced non-small cell lung cancer (NSCLC), probably due to the fact that standard dosing may not be effective in all patients. The aim of the present review was to address some criticisms associated with the radiotherapy image-guided in NSCLC. Materials and Methods: A systematic literature search was conducted. Only published articles that met

APA, Harvard, Vancouver, ISO, and other styles

37

Salama, Joseph K., and Everett E. Vokes. "New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer." Journal of Clinical Oncology 31, no. 8 (2013): 1029–38. http://dx.doi.org/10.1200/jco.2012.44.5064.

Full text

Abstract:

Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with technologic strides in radiotherapy have the potential to improve outcomes for patients with non–small-cell lung cancer (NSCLC). Investigations are ongoing to identify optimal cytotoxin-based chemoradiotherapy platforms. The influence of specific histologic and molecular mutation status on the combination of targeted therapies and radiotherapy is also being actively studied. Although there are no convincing randomized phase III data to date supporting a survival advantage for combining molecularly targeted ag

APA, Harvard, Vancouver, ISO, and other styles

38

Wang, JZ, AP Landry, V. Patil, et al. "GR.6 Meningioma molecular classification predicts response to surgery and adjuvant radiotherapy: an integrated clinicomolecular analysis & prospective validation." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 51, s1 (2024): S2. http://dx.doi.org/10.1017/cjn.2024.73.

Full text

Abstract:

Background: Meningiomas are the most common intracranial tumor with surgery, dural margin treatment, and radiotherapy as cornerstones of therapy. Response to treatment continues to be highly heterogeneous even across tumors of the same grade. Methods: Using a cohort of 2490 meningiomas in addition to 100 cases from the prospective RTOG-0539 phase II clinical trial, we define molecular biomarkers of response across multiple different, recently defined molecular classifications and use propensity score matching to mimic a randomized controlled trial to evaluate the role of extent of resection, d

APA, Harvard, Vancouver, ISO, and other styles

39

Skouri, M., Z. Naimi, M. Bohli, et al. "P104 Hypofractionated radiotherapy in triple negative breast cancer: Does molecular subtype impact radiotherapy outcomes ?" Breast 68 (April 2023): S54—S55. http://dx.doi.org/10.1016/s0960-9776(23)00221-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Król, Katarzyna, Anna Mazur, Paulina Stachyra-Strawa, and Ludmiła Grzybowska-Szatkowska. "Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review." International Journal of Molecular Sciences 24, no. 6 (2023): 5858. http://dx.doi.org/10.3390/ijms24065858.

Full text

Abstract:

Lung cancer is the leading cause of death worldwide for both men and women. Surgery can be offered as a radical treatment at stages I and II and selected cases of stage III (III A). Whereas at more advanced stages, combined modalities of treatment are applied: radiochemotherapy (IIIB) and molecularly targeted treatment (small molecule tyrosine kinase inhibitors, VEGF receptor inhibitors, monoclonal antibodies, and immunological treatment with monoclonal antibodies). Combination treatment, composed of radiotherapy and molecular therapy, is increasingly employed in locally advanced and metastati

APA, Harvard, Vancouver, ISO, and other styles

41

Feofanova, Natália, Jony Marques Geraldo, and Lídia Maria de Andrade. "Radiation OncologyIn Vitro: Trends to Improve Radiotherapy through Molecular Targets." BioMed Research International 2014 (2014): 1–13. http://dx.doi.org/10.1155/2014/461687.

Full text

Abstract:

Much has been investigated to improve the beneficial effects of radiotherapy especially in that case where radioresistant behavior is observed. Beyond simple identification of resistant phenotype the discovery and development of specific molecular targets have demonstrated therapeutic potential in cancer treatment including radiotherapy. Alterations on transduction signaling pathway related with MAPK cascade are the main axis in cancer cellular proliferation even as cell migration and invasiveness in irradiated tumor cell lines; then, for that reason, more studies are in course focusing on, am

APA, Harvard, Vancouver, ISO, and other styles

42

Davis, LauraMay, April-Louise Smith, Matthew D. Aldridge, et al. "Personalisation of Molecular Radiotherapy through Optimisation of Theragnostics." Journal of Personalized Medicine 10, no. 4 (2020): 174. http://dx.doi.org/10.3390/jpm10040174.

Full text

Abstract:

Molecular radiotherapy, or targeted radionuclide therapy, uses systemically administered drugs bearing a suitable radioactive isotope, typically a beta emitter. These are delivered via metabolic or other physiological pathways to cancer cells in greater concentrations than to normal tissues. The absorbed radiation dose in tumour deposits causes chromosomal damage and cell death. A partner radiopharmaceutical, most commonly the same vector labelled with a different radioactive atom, with emissions suitable for gamma camera or positron emission tomography imaging, is used to select patients for

APA, Harvard, Vancouver, ISO, and other styles

43

Bridgewater, John A., Karyn A. Goodman, Aparna Kalyan, and Mary F. Mulcahy. "Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling." American Society of Clinical Oncology Educational Book 36 (2016): e194-e203. http://dx.doi.org/10.14694/edbk_160831.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Bridgewater, John A., Karyn A. Goodman, Aparna Kalyan, and Mary F. Mulcahy. "Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling." American Society of Clinical Oncology Educational Book, no. 36 (May 2016): e194-e203. http://dx.doi.org/10.1200/edbk_160831.

Full text

Abstract:

Biliary tract cancer, or cholangiocarcinoma, arises from the biliary epithelium of the small ducts in the periphery of the liver (intrahepatic) and the main ducts of the hilum (extrahepatic), extending into the gallbladder. The incidence and epidemiology of biliary tract cancer are fluid and complex. It is shown that intrahepatic cholangiocarcinoma is on the rise in the Western world, and gallbladder cancer is on the decline. Radiation therapy has emerged as an important component of adjuvant therapy for resected disease and definitive therapy for locally advanced disease. The emerging sophist

APA, Harvard, Vancouver, ISO, and other styles

45

Pollock, Jondavid. "Molecular tumor profile: another consideration for postmastectomy radiotherapy." Community Oncology 8, no. 9 (2011): 427. http://dx.doi.org/10.1016/s1548-5315(12)70094-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Hauslermans, K. "93 speaker ADAPTIVE RADIOTHERAPY BY MOLECULAR IMAGING CHANGES." Radiotherapy and Oncology 99 (May 2011): S34. http://dx.doi.org/10.1016/s0167-8140(11)70216-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Wedge, S. R., K. J. Williams, and I. J. Stratford. "135 INVITED Combining molecular targeted agents with radiotherapy." European Journal of Cancer Supplements 5, no. 4 (2007): 37. http://dx.doi.org/10.1016/s1359-6349(07)70249-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Carpenter, C. M., G. Pratx, C. Sun, and L. Xing. "Toward Molecular Image-guidance for Intraoperative Breast Radiotherapy." International Journal of Radiation Oncology*Biology*Physics 81, no. 2 (2011): S90. http://dx.doi.org/10.1016/j.ijrobp.2011.06.183.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Chung, T. D. "Molecular Targeting in Radiotherapy: Epidermal Growth Factor Receptor." Molecular Interventions 5, no. 1 (2005): 15–19. http://dx.doi.org/10.1124/mi.5.1.5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Katti, K. V., R. Kannan, K. Katti, et al. "Hybrid gold nanoparticles in molecular imaging and radiotherapy." Czechoslovak Journal of Physics 56, S4 (2006): D23—D34. http://dx.doi.org/10.1007/s10582-006-0484-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!